Acute Myeloid Leukemia News and Research

RSS

Acute Myeloid Leukemia (AML) is a rapidly progressing cancer of the blood characterized by the uncontrolled proliferation of immature blast cells in the bone marrow. The Leukemia and Lymphoma Society estimates that over 13,000 new cases of AML were diagnosed and approximately 9,000 deaths from AML occurred in the U.S. during 2007. AML is generally a disease of older adults, and the median age of a patient diagnosed with AML is about 67 years. A majority of elderly patients are not considered candidates for standard induction therapy or decline therapy, resulting in an acute need for new treatment options.

Experimental drug CS18 shows promise for overcoming cancer treatment resistance

Researchers at Baylor College of Medicine have developed a drug called CS18 that disrupts the ability of cancer cells to survive therapy. The findings, published in Science Advances, support exploring the possibility of using CS18 to treat human cancer in the future.

5 Aug 2026

New AI score enhances monitoring of myelodysplastic neoplasms

Weill Cornell Medicine investigators have developed a new AI-based method to assess patients with a form of blood cancer called myelodysplastic neoplasms.

20 Jul 2026

Researchers uncover new T cell attack mechanism against acute myeloid leukemia

Researchers at The University of Texas MD Anderson Cancer Center have discovered a new way in which T cells attack acute myeloid leukemia (AML) cells, which may help explain why AML is particularly sensitive to immune-based treatments and could guide the development of future cancer immunotherapies.

15 Jul 2026

New therapy targets Hippo pathway to fight treatment-resistant acute myeloid leukemia

Researchers at The University of Texas MD Anderson Cancer Center have discovered that an investigational epigenetic therapy remained effective in treatment-resistant acute myeloid leukemia (AML) through activating the Hippo pathway, a tumor-suppressing pathway linked to cancer growth and drug resistance.

13 Jul 2026

Strategic collaboration funds interdisciplinary projects to improve cancer care

Rice University's Synthesis X Center and Houston Methodist Neal Cancer Center have awarded $90,000 in seed grants as part of a new strategic collaboration.

8 Jul 2026

Study explains how leukemia creates inflammatory lung environments

Acute myeloid leukemia (AML) does more than infiltrate the lungs: it also transforms lung tissue to create an inflammatory environment that promotes the expansion of tumor cells and impairs respiratory function.

30 Jun 2026

Study reveals how leukemia cells invade lungs and cause breathing problems

Led by NYU Langone Health researchers, a new study shows how blood cancer cells enter the lungs, damage tissue, and cause severe breathing problems.

29 Jun 2026

Gene fusion patterns refine classification of rare acute leukemias

Acute leukemias with chimeric fusion genes involving FET (FUS, EWSR1, and TAF15) family proteins and ETS (E26 transformation-specific)-like transcription factors often present with unique clinical and pathological characteristics.

27 Jun 2026

New all-oral regimen improves treatment convenience for AML patients

The ASCERTAIN V clinical trial demonstrated that an all-oral drug combination for older patients with acute myeloid leukemia (AML) is an effective alternative to the current standard, which requires repeated hospital or office visits for intravenous treatment.

3 Jun 2026

Roswell Park scientists present five key cancer studies at clinical meeting

The research findings of experts from Roswell Park Comprehensive Cancer Center will be featured during the American Society of Clinical Oncology (ASCO) annual meeting May 29 to June 2 at McCormick Place in Chicago.

25 May 2026

Loss of X chromosome linked to female infertility risk

Chromosomes carry genetic information for biological sex, which generally assigns women two X chromosomes and men XY chromosomes.

12 May 2026

Diverse leukemia stem cells may drive AML relapse after therapy

Scientists from the German Cancer Research Center (DKFZ) and the HI-STEM* Stem Cell Institute have deciphered a key mechanism that contributes to treatment failure in acute myeloid leukemia (AML).

7 May 2026

From killers to strategists: CAR T cells enter their multifunctional era

A review of 1,801 registered CAR T clinical trials shows that multifunctional designs now account for 533 trials and 33% of new CAR T products submitted for clinical testing in 2025. The field is shifting toward multitargeted, safety-controlled, cytokine-secreting, and checkpoint-modulating CAR T cells, but manufacturing, regulation, and limited clinical outcome data remain key barriers.

30 Apr 2026

Early life exposure to PFAS associated with common childhood leukemia

Early exposure to PFAS, a group of widely used compounds known as "forever chemicals," was associated with a higher risk of acute lymphoblastic leukemia, the most common childhood cancer, according to University of California, Irvine Joe C. Wen School of Population & Public Health researchers.

27 Apr 2026

New strategy boosts natural killer cells to fight cancer

Scientists have developed a strategy to boost the cancer-fighting power of natural killer (NK) cells, part of the immune system's first line of defense.

24 Apr 2026

New target CD43 may improve leukemia immunotherapy outcomes

Macrophages, much like Alice of "Alice in Wonderland," recognize and consume tumor cells that display "eat me" surface markers.

11 Apr 2026

Study finds increasing rates of therapy-related acute myeloid leukemia

Some therapies used to treat cancer may increase the risk of later developing cancers that affect the blood.

6 Apr 2026

Fertility treatments linked to small increases in some cancers

Findings indicate small increases in certain cancers linked to assisted reproduction, though overall cancer incidence aligns with the general female population.

13 Mar 2026

Trial highlights promising frontline therapy for blastic plasmacytoid dendritic cell neoplasm

Seventy-five percent of patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN) who were treated with the antibody-drug conjugate (ADC) pivekimab sunirine (PVEK) had a complete response, according to new data from the Phase I/II multicenter international CADENZA trial led by researchers at The University of Texas MD Anderson Cancer Center.

11 Feb 2026

New study exposes a targetable vulnerability in acute myeloid leukemia

New research co-led by Indiana University School of Medicine scientists has exposed a vulnerability in acute myeloid leukemia by identifying the blood cancer's reliance on a specific signaling pathway involved in the body's inflammation response.

19 Jan 2026